NF-kappaB Signaling
Phospho-IKK-α/β (Ser176/180) Blocking Peptide
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1023S | 100 μg | 16,000 | |
|
IKK抗体製品一覧
| 使用目的 | |
| Phospho-IKK-α/β (Ser176/180) (16A6) Rabbit mAb (#2697)の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Phospho-IKK-alpha/beta (Ser176/180) (16A6) Rabbit mAb #2697 in the presence of control peptide (left) or Phospho-IKK-alpha/beta (Ser176/180) Blocking Peptide (right).
The NF-κB/Rel transcription factors are present in the cytosol in an inactive state, complexed with the inhibitory IκB proteins (1-3). Most agents that activate NF-κB do so through a common pathway based on phosphorylation-induced, proteasome-mediated degradation of IκB (3-7). The key regulatory step in this pathway involves activation of a high molecular weight IκB kinase (IKK) complex whose catalysis is generally carried out by three tightly associated IKK subunits. IKKα and IKKβ serve as the catalytic subunits of the kinase and IKKγ serves as the regulatory subunit (8,9). Activation of IKK depends upon phosphorylation of Ser177 and Ser181 in the activation loop of IKKβ (Ser176 and Ser180 in IKKα), which causes conformational changes resulting in kinase activation (10-13).
-
Baeuerle, P.A. and Baltimore, D. (1988) Science 242, 540-6.
-
Beg, A.A. and Baldwin, A.S. (1993) Genes Dev 7, 2064-70.
-
Finco, T.S. et al. (1994) Proc Natl Acad Sci USA 91, 11884-8.
-
Brown, K. et al. (1995) Science 267, 1485-8.
-
Brockman, J.A. et al. (1995) Mol Cell Biol 15, 2809-18.
-
Traenckner, E.B. et al. (1995) EMBO J 14, 2876-83.
-
Chen, Z.J. et al. (1996) Cell 84, 853-62.
-
Zandi, E. et al. (1997) Cell 91, 243-52.
-
Karin, M. (1999) Oncogene 18, 6867-74.
-
DiDonato, J.A. et al. (1997) Nature 388, 548-54.
-
Mercurio, F. et al. (1997) Science 278, 860-6.
-
Johnson, L.N. et al. (1996) Cell 85, 149-58.
-
Delhase, M. et al. (1999) Science 284, 309-13.